Loomis, Sayles & Company
SRPT icon

Loomis, Sayles & Company’s Sarepta Therapeutics SRPT Stock Holding History

Loomis, Sayles & Company’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-41
Closed -$5K – 1017
2023
Q2 		$5K Buy
41
+13
+46% +$1.68K ﹤0.01% 865
2023
Q1 		$4K Sell
28
-107
-79% -$13.9K ﹤0.01% 918
2022
Q4 		$17K Sell
135
-3,071
-96% -$356K ﹤0.01% 737
2022
Q3 		$354K Buy
+3,206
New +$323K ﹤0.01% 441
2021
Q1 		– Sell
-72
Closed -$12K – 889
2020
Q4 		$12K Buy
+72
New +$10.7K ﹤0.01% 699

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Loomis, Sayles & Company's SRPT Position: Q3 2023 in Review

Loomis, Sayles & Company sold out of Sarepta Therapeutics (SRPT) in Q3 2023, closing a stake of 41 shares — an estimated $5K sold.

Loomis, Sayles & Company first reported a position in SRPT in Q4 2020 and held it in 5 quarters. The position peaked at $354K in Q3 2022. 394 funds tracked by Wall St. Rank hold SRPT as of Q3 2023.

  • Loomis, Sayles & Company reported no remaining Sarepta Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Loomis, Sayles & Company sold 41 Sarepta Therapeutics shares in Q3 2023, an estimated $5K.
  • Loomis, Sayles & Company first reported a position in Sarepta Therapeutics in Q4 2020 and held it in 5 quarters.
  • Loomis, Sayles & Company's Sarepta Therapeutics position peaked at $354K in Q3 2022.
  • 394 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2023.

Based on Loomis, Sayles & Company's 13F filing for Q3 2023, filed 9 Nov 2023.